77 results
6-K
EX-99.1
PHXM
PHAXIAM Therapeutics S.A.
26 Sep 23
I.Certification of the Person Responsible for the Half-year Financial Report
3:01pm
their efficacy in lung, blood and urinary tract infections, in addition to the three major targets already developed (S. aureus, P. aeruginosa, and E. coli … , blood and urinary tract infections, in addition to the three major targets already developed (S. aureus, P. aeruginosa, and E. coli).
On September 21
6-K
EX-99.1
PHXM
PHAXIAM Therapeutics S.A.
21 Sep 23
Current report (foreign)
8:42am
targets already developed (S. aureus, P. aeruginosa, E. coli)
Lyon (France) and Cambridge (MA, US), September 19, 2023 – 07:00 a.m. CEST – PHAXIAM … strains of this bacterium have recently extended its potential targets to people with no health problems.
In Western countries, we estimate
6-K
EX-99.1
PHXM
PHAXIAM Therapeutics S.A.
24 May 23
Exemption Document Prepared In Connection with the Merger by Absorption of Pherecydes Pharma by Erytech Pharma
8:25am
clinical portfolio of targets in the fight against resistant bacterial infections.
Capitalize on Erytech’s presence in the United States to facilitate … targets:
As of 01/19/2023, Erytech Pharma’s share price is monitored by Cowen, JMP, Kempen and ODDO BHF, with Jefferies no longer covering Erytech Pharma
6-K/A
EX-99.1
PHXM
PHAXIAM Therapeutics S.A.
12 Sep 22
I.Certification of the Person Responsible for the Half-year Financial Report
4:33pm
for patients with high unmet medical needs. Our lead product candidate eryaspase, which we also refer to as GRASPA®, targets the metabolism of cancer cells
6-K
EX-99.1
PHXM
PHAXIAM Therapeutics S.A.
12 Sep 22
I.Certification of the Person Responsible for the Half-year Financial Report
12:04pm
of product candidates for patients with high unmet medical needs. Our lead product candidate eryaspase, which we also refer to as GRASPA®, targets
6-K
EX-99.1
inbbloguj y8
28 Jun 22
Current report (foreign)
9:01am
6-K
EX-99.1
qtxr1mnocr
25 May 22
Current report (foreign)
8:11am
6-K
EX-99.1
z6m8tzi1kh h65lie1r
13 May 22
ERYTECH Provides Business and Financial Update for the First Quarter of 2022
11:37am
6-K
EX-99.1
bd2de5
2 May 22
ERYTECH Announces Filing of 2021 Universal Registration Document and 2021 Annual Report on Form 20-F, as well as its 2022 financial calendar
9:47am
6-K
EX-99.1
u98vx7d0ntv0eez7o7
25 Apr 22
Current report (foreign)
4:31pm
6-K
EX-99.1
445x3c3j8e
15 Mar 22
ERYTECH Provides Business and Financial Update for the Fourth Quarter and Full Year 2021
9:19am
6-K
EX-99.1
6tg1f ud0jap2sstk0e
10 Feb 22
ERYTECH Expands Patent Portfolio for the Treatment of Rare Metabolic Diseases
8:19am
6-K
EX-99.1
4xjir
27 Jan 22
ERYTECH Announces Presentation of
1:20pm
6-K
EX-99.2
lv6lo1a
16 Dec 21
Erytech Announces Presentation of Results of Expanded Access Program In All at 2021 Ash Annual Meeting and Acceptance of Two Abstracts at Asco Gi
5:23pm
6-K
EX-99.1
6tcnrxsf
16 Dec 21
Erytech Announces Presentation of Results of Expanded Access Program In All at 2021 Ash Annual Meeting and Acceptance of Two Abstracts at Asco Gi
5:23pm
424B5
1j9sebpojp 4mlpvy
16 Dec 21
Prospectus supplement for primary offering
5:21pm
6-K
EX-99.1
rgdvnc8
30 Nov 21
ERYTECH Secures US Patent Directed to Sequential Use of Methioninase & Asparaginase against Solid Tumors
10:32am
6-K
EX-99
qpm0gz0jxbtgsvmp1p7
16 Nov 21
Current report (foreign)
2:22pm
6-K
EX-99.1
9jn1dr3o ih44
25 Oct 21
ERYTECH Announces Results from TRYbeCA-1 Phase 3
10:59am